The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review

Clicks: 2
ID: 326535
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #190 of 202 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: Immune thrombocytopenia (ITP) carries an increased thrombotic risk, especially when associated with autoimmune conditions and/or antiphospholipid antibody (aPL) positivity. The burden of thrombotic events in patients treated with second-line therapies in these instances has not been systematically studied. METHODS: Medline and Embase were searched from 2010 to November 16th, 2025, for studies on high-risk ITP patients receiving eligible second-line treatments, including thrombopoietin receptor agonists (TPO-RAs), fostamatinib, rituximab, other immune suppressants (cyclosporine, cyclophosphamide, azathioprine and mycophenolate) and splenectomy. High-risk ITP was defined as (1) primary ITP (pITP) with aPL positivity or (2) secondary ITP (sITP) when associated to an autoimmune disease posing an increased thrombotic risk. The primary outcome was the frequency of any thrombotic event during follow-up. Secondary outcomes were the separate frequencies of arterial and venous thromboses, overall and stratified by treatment. RESULTS: We included 13 studies providing data of 308 high-risk ITP patients on at least one eligible second-line treatment. Thrombosis occurred in 40 patients (10%, 95% CI 5-19) over a median follow-up ranging from 6 to 42 months. Stratifying by treatment, thrombosis occurred in 30 patients on TPO-RAs (16%, 95% CI 11-22), in 3 on rituximab (14%, 95% CI 3-35), in 3 on immune suppressants (11%, 95% CI 2-28) and in 6 who underwent splenectomy (12%, 95% CI 4-24). CONCLUSION: We have found a consistent thrombotic burden in high-risk ITP patients on second-line therapy, evident across all examined treatment options, underscoring the pro-thrombotic immune milieu of this population and the need for tailored risk-mitigation strategies.
Reference Key
openalex_W7204264914 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elisa Tarasconi, Bianca Clerici, Giulia Marcucci, Eleonora Pontisso, Chiara Mondini, Chiara Pisetta, Simone Birocchi, Tommaso Schioppo, Gian Marco Podda
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag461
URL
https://doi.org/10.1093/rheumatology/keag461
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.